Evidence map›Paper›PMID 33840589›Full record

ArticleCytokine2021

Aberrant cytokine expression in COVID-19 patients: Associations between cytokines and disease severity.

Yueting Tang, Jiayu Sun, Huaqin Pan, Fen Yao, Yumeng Yuan, Mi Zeng, Guangming Ye, Gui Yang, Bokun Zheng, Junli Fan and 8 more

Open access · greenAbstract read
In one paragraph

Article in Cytokine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. SARS-CoV-2-derived RNA replicons as safe and effective vaccines.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Yueting TangDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 86-027-67812888, China. Electronic address: anzhitinglan723@sina.com.
Jiayu SunDepartment of Cell Biology, Shantou University Medical College, Shantou, Guangdong, China. Electronic address: 18jysun1@stu.edu.cn.
Huaqin PanDepartment of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 86-027-67813517, China. Electronic address: phq2012@whu.edu.cn.
Fen YaoDepartment of Cell Biology, Shantou University Medical College, Shantou, Guangdong, China. Electronic address: fyao@stu.edu.cn.
Yumeng YuanDepartment of Cell Biology, Shantou University Medical College, Shantou, Guangdong, China. Electronic address: 19ymyuan@stu.edu.cn.
Mi ZengDepartment of Cell Biology, Shantou University Medical College, Shantou, Guangdong, China. Electronic address: 20mzeng1@stu.edu.cn.
Guangming YeCenter for Clinical Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. Electronic address: fduser@163.com.
Gui YangDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 86-027-67812888, China. Electronic address: 2932485805@qq.com.
Bokun ZhengDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 86-027-67812888, China. Electronic address: 2020203030025@whu.edu.cn.
Junli FanDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 86-027-67812888, China. Electronic address: 527450105@qq.com.
Yunbao PanDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 86-027-67812888, China. Electronic address: panyunbao@outlook.com.
Ziwu ZhaoDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 86-027-67812888, China. Electronic address: 812466394@qq.com.
Shuang GuoDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 86-027-67812888, China. Electronic address: 824368669@qq.com.
Yinjuan LiuDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 86-027-67812888, China. Electronic address: liuyingjuan811@163.com.
Fanlu LiaoDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 86-027-67812888, China. Electronic address: alya0816@126.com.
Yongwei DuanDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 86-027-67812888, China. Electronic address: 742093090@qq.com.
Xiaoyang JiaoDepartment of Cell Biology, Shantou University Medical College, Shantou, Guangdong, China. Electronic address: xyjiao@stu.edu.cn.
Yirong LiDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 86-027-67812888, China. Electronic address: liyirong838@163.com.
Wuhan University · CNShantou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytokines play pleiotropic, antagonistic, and collaborative in viral disease. The high morbidity and mortality of coronavirus disease 2019 (COVID-19) make it a significant threat to global public health. Elucidating its pathogenesis is essential to finding effective therapy. A retrospective study was conducted on 71 patients hospitalized with COVID-19. Data on cytokines, T lymphocytes, and other clinical and laboratory characteristics were collected from patients with variable disease severity. The effects of cytokines on the overall survival (OS) and event-free survival (EFS) of patients were analyzed. The critically severe and severe patients had higher infection indexes and significant multiple organ function abnormalities than the mild patients (P < 0.05). IL-6 and IL-10 were significantly higher in the critically severe patients than in the severe and mild patients (P < 0.05). IL-6 and IL-10 were closely associated with white blood cells, neutrophils, T lymphocyte subsets, D-D dimer, blood urea nitrogen, complement C1q, procalcitonin C-reactive protein. Moreover, the IL-6 and IL-10 levels were closely correlated to dyspnea and dizziness (P < 0.05). The patients with higher IL-10 levels had shorter OS than the group with lower levels (P < 0.05). The older patients with higher levels of single IL-6 or IL-10 tended to have shorter EFS (P < 0.05), while the patients who had more elevated IL-6 and IL-10 had shorter OS (P < 0.05). The Cox proportional hazard model revealed that IL-6 was the independent factor affecting EFS. IL-6 and IL-10 play crucial roles in COVID-19 prognosis.

Indexed as

AdultAgedAge FactorsAgingBlood Coagulation FactorsCOVID-19Cytokine Release SyndromeFemaleHumansInterleukin-10Interleukin-6Lymphocyte CountMaleMiddle AgedRetrospective StudiesSARS-CoV-2Blood Coagulation FactorsIL10 protein, humanIL6 protein, humanInterleukin-10Interleukin-6COVID-19CytokinesDisease severitySurvivalT lymphocyte

Identifiers

PMID33840589
PMCPMC8011640
OpenAlexW3145300561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.